Statistics from Altmetric.com
Opiate-receptor blockade as therapy for Crohn’s disease?
The search for new treatments in Crohn’s disease never stops. Endogenous opiates are known to influence both growth and immunity, and Met5-enkephalin has effects on a number of immune effector cells. Low-dose naltrexone can produce intermittent blockade of opioid receptors, resulting in a rise in tissue levels of Met5-enkaphalin and endorphins. Naltrexone has been used to aid healing of corneal abrasions and is known to block tumour necrosis factor (TNF)-α synthesis. Stimulators of μ-opioid receptors reduce inflammation in the trinitrobenzenesulphonic acid (TNB) colitis model in mice.
The authors designed a prospective, pilot study of low-dose naltrexone (4.5 mg at night, compared with the usual 50 mg dose used in alcohol or opioid abuse) given for 12 weeks to a group of 17 patients with moderate to severe active Crohn’s disease (Crohn’s Disease Activity Index (CDAI) score >220). Most patients had previously received infliximab, but not for at least 8 weeks prior to the study. Other medications for Crohn’s disease were kept stable during the study (47% were taking immunomodulators and 24% were taking corticosteroids).
Within 4 weeks, there was a …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.